Website
News25/Ratings3
News · 26 weeks530%
2025-10-262026-04-19
Mix1790d
- Other12(71%)
- SEC Filings3(18%)
- Earnings2(12%)
Latest news
25 items- PRCo-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholdersSALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate in the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026. The Company will present the Co-Dx Mycobacterium tuberculosis ("MTB" or "TB") test on the Co-Dx PCR platform* during a roundtable discussion with U.S. government agencies and other U.S.-based private sector companies.
- PRCo-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, GermanyCompany to engage with global customers and distributors while expanding international commercial relationshipsSALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will participate in the Congress of the European Society of Clinical Microbiology and Infectious Disease ("ESCMID Global") 2026, taking place April 17-21 in Munich, Germany. ESCMID Global 2026 features academic and industry programming that
- PRCo-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC UtahTrade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and moreSALT LAKE CITY, April 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company executives will be participating in the latest World Trade Center (WTC) Utah trade mission with Utah Governor Cox and the Governor's Office of Economic Opportunity, taking place April 13-22 in locations across Switzerland and Germany.
- PRCo-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial CityFacility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi ArabiaSALT LAKE CITY, April 2, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoMira Diagnostics ("CoMira"), the Company's joint venture ("JV") with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia ("KSA"), has secured an industrial land allocation in Sudair Industrial City located in the Riyadh region, one of Saudi Arabia's leading industrial hubs, followin
- SECSEC Form 10-K filed by Co-Diagnostics Inc.10-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Reports Full Year 2025 Financial ResultsAdvancing Global Commercialization Strategy Through CoSara and CoMira Joint VenturesProgressing Clinical Pipeline and Regulatory Pathways for PCR PlatformStrengthening Technology Leadership with AI Integration and Expanding IP PortfolioSALT LAKE CITY, March 31, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financia
- PRCo-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health OrganizationThe near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and utilizing tongue swab samplesNew recommendations are aligned with the design of Co-Dx's proprietary test, platform, and missionSALT LAKE CITY, March 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has commenced shipments of PCR Pro® instruments*, Co-Dx™ PCR MTB test kits* for tuberculosis ("TB"), and proprietary sample preparation instruments to its joint vent
- PRCo-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South AsiaExpansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro® and SARAGENE® product lineSALT LAKE CITY, March 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company has signed an agreement for CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited ("ASE Group"), to significantly expand its commercial and distribution territory across South Asia to now includ
- PRCo-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and WebcastSALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its fourth quarter and full year 2025 financial results on Tuesday, March 31, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
- PRCo-Diagnostics to Present at Medical Korea 2026Co-Dx to join WTC Utah and other Utah legislative and industry delegates March 19-22 in Seoul, South KoreaSALT LAKE CITY, March 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Co-Dx will accompany World Trade Center (WTC) Utah, the Utah Governor's Office of Economic Opportunity (GOEO), BioUtah, and other legislative and industry leaders at Medical Korea 2026, taking place March 19-22 in Seoul, South Korea.
- PRCo-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform TechnologiesSALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Japan Patent Office ("JPO") has granted Japanese Patent No. 7797537, titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis." The patent further strengthens Co-Dx's intellectual property portfolio and supports the innovativeness of its novel Co-Dx PCR Pro® instrument, test cups, and other aspects of the point-of-care platform*.
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Regains Compliance with Nasdaq Listing RequirementsSALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 9, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price rule. As a result, the previously disclosed listing matter has been closed and the Company's shares will resume trading on Nasdaq effective March 11, 2026.
- PRCo-Diagnostics to Showcase PCR Platform at World Health Expo Labs DubaiSALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in an exhibition at the upcoming World Health Expo Labs Dubai ("WHX Labs"), taking place February 10–13, 2026, at the Dubai World Trade Centre. World Health Expo Labs Dubai, formerly Medlab Middle East, is a multi-day international exhibition that convenes laboratory professionals, healthcare leaders, diagnostics develo
- PRCo-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ InstrumentCDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has received a license from the Central Drugs Standard Control Organization ("CDSCO") to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument for sale or distribution.
- PRCo-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR PlatformCompany and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform SALT LAKE CITY, Feb. 4, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has successfully completed the necessary audits of its quality management system ("QMS") and that its manufacturing facility located in Vadodara, India, has been granted ISO 13485:2016 certificati
- SECSEC Form S-8 filed by Co-Diagnostics Inc.S-8 - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor RelationshipsSALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences. The events provided opportunities for CoSara to introduce its SARAGENE® diagnos
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Announces Reverse Stock SplitSALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx's common stock will continue to trade on The Nasdaq Capital Market under the symbol "CODX" and will begin trading on a split-adjusted basis when the market opens on Friday, January
- PRCo-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform TechnologiesThe Australian patent represents the first patent granted for the Company's new point-of-care testing platform SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*. Initially filed in May 2022 before being granted i
- SECSEC Form 424B5 filed by Co-Diagnostics Inc.424B5 - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, IndiaSALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR). The event will take place December 15-19, 2025 at the ICMR–National Institute for Research in Tuberculosis (NIRT) located in Chennai, India.